Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4560683
Max Phase: Preclinical
Molecular Formula: C100H119Cl2N11O31
Molecular Weight: 2042.00
Molecule Type: Unknown
Associated Items:
ID: ALA4560683
Max Phase: Preclinical
Molecular Formula: C100H119Cl2N11O31
Molecular Weight: 2042.00
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](OC(=O)NCCNC(=O)[C@H]3NC(=O)[C@H]4NC(=O)[C@H](NC(=O)[C@@H]5NC(=O)C6NC(=O)[C@@H](Cc7ccc(c(Cl)c7)Oc7cc5cc(c7O)Oc5ccc(cc5Cl)[C@H]4O)NC(=O)[C@H](N)c4ccc(O)c(c4)Oc4cc(O)cc6c4)c4ccc(O)c(c4)-c4c(O)cc(O)cc43)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@H]2OC(=O)O[C@]21C
Standard InChI: InChI=1S/C100H119Cl2N11O31/c1-15-71-100(10)85(143-97(131)144-100)46(6)113(13)41-42(2)39-98(8,132)84(141-95-81(120)62(112(11)12)26-43(3)134-95)44(4)83(45(5)94(129)139-71)140-72-40-99(9,133-14)86(47(7)135-72)142-96(130)105-25-24-104-89(124)78-58-37-55(115)38-65(118)73(58)57-31-50(18-20-63(57)116)75-90(125)111-79(93(128)110-78)80(119)51-19-23-67(60(102)32-51)138-70-35-53-34-69(82(70)121)137-66-22-16-48(27-59(66)101)28-61-87(122)107-76(91(126)109-77(53)92(127)108-75)52-29-54(114)36-56(30-52)136-68-33-49(17-21-64(68)117)74(103)88(123)106-61/h16-23,27,29-38,42-47,61-62,71-72,74-81,83-86,95,114-121,132H,15,24-26,28,39-41,103H2,1-14H3,(H,104,124)(H,105,130)(H,106,123)(H,107,122)(H,108,127)(H,109,126)(H,110,128)(H,111,125)/t42-,43-,44+,45-,46-,47+,61-,62+,71-,72+,74-,75-,76?,77-,78+,79+,80-,81-,83+,84-,85-,86+,95+,98-,99-,100+/m1/s1
Standard InChI Key: WWNJYNMANNTTGS-QBRGGOTISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2042.00 | Molecular Weight (Monoisotopic): 2039.7451 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Tevyashova AN, Bychkova EN, Korolev AM, Isakova EB, Mirchink EP, Osterman IA, Erdei R, Szücs Z, Batta G.. (2019) Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides., 29 (2): [PMID:30473176] [10.1016/j.bmcl.2018.11.038] |
Source(1):